Breaking News: Promising Results Revealed for Furmonertinib at 2023 Lung Cancer Conference – Allist and Arrivent Share Exciting Update!
Furmonertinib Study Shows Promising Results for NSCLC Patients Exciting News in the Fight Against Lung Cancer SHANGHAI, China, Sept. 10, 2023 (GLOBE NEWSWIRE) — Allist Pharmaceuticals Co., Ltd. (“Allist”) and ArriVent Biopharma, Inc. (“ArriVent”) have come together to announce interim results from the Phase Ib clinical study FAVOUR. This study focuses on evaluating the efficacy…